Development of anti-tumor gene therapy for retinoblastoma using Sendai virus vector and IFNB gene.

我们研究了M基因缺陷仙台病毒载体编码IFN-β基因（SeV/ΔM-IFN-β）的抗肿瘤基因治疗是否具有治疗视网膜母细胞瘤的潜力。虽然SeV/ΔM载体在视网膜母细胞瘤细胞系中的基因转导效率较低，但它在视网膜色素上皮（RPE）来源的细胞系中介导了高效的基因转移。SeV/ΔM-mediated在RPE中过表达IFN-β抑制了视网膜母细胞瘤细胞的生长，提示使用SeV/ΔM载体眼内转移IFN-β基因可能是阻止视网膜母细胞瘤患者肿瘤生长的有效策略。

We investigated weather anti-tumor gene therapy using M gene deficient Sendai virus vector encoding IFN-β gene (SeV/ΔM-IFN-β) has therapeutic potentials for the treatment of retinoblastoma. Whereas the gene transduction efficiency of SeV/ΔM vector is low in retinoblastoma cell lines, it mediates efficient gene transfer in a retinal pigment epithelium (RPE)-derived cell line. SeV/ΔM-mediated overexpression of IFN-β in RPE suppressed the growth of retinoblastoma cells, suggesting that intraocular IFN-β gene transfer using SeV/ΔM vector may be a useful strategy for preventing tumor growth in retinoblastoma patients.